By Tort Law Team 
In 2024, the Centers for Medicare & Medicaid Services finalized rules that upended how Medicare Advantage plans pay agents, brokers, and third-party marketing organizations. Industry groups immediately challenged the changes in court. On August 18, 2025, a Texas federal judge delivered a clear verdict: key compensation limits and contract restrictions went too far, while one data-privacy safeguard stayed intact.
This article breaks down the Medicare Advantage marketing rule judge decision in plain terms. Compliance officers, MA plan executives, brokers, TPMOs, and legal counsel will find a practical map of what was vacated, what remains enforceable, and how the post-Loper Bright landscape reshapes CMS authority. Understanding these boundaries helps stakeholders adjust contracts, compensation models, and compliance programs with confidence ahead of future rulemaking cycles.
Background: The 2024 CMS Final Rule and Its Targets
CMS issued its Contract Year 2025 Final Rule in April 2024 amid rising complaints about aggressive marketing and misaligned incentives. Senate Finance Committee investigations had highlighted practices such as volume bonuses, inflated administrative payments framed as “add-ons,” and pressure to enroll beneficiaries in plans that did not match their needs.
The rule focused on three main areas under the long-standing agent and broker compensation framework in 42 C.F.R. §§ 422.2274 and 423.2274:
- A Fixed Fee that treated certain administrative payments as “compensation” and capped them at $100 per enrollment while adjusting the fair-market-value (FMV) compensation ceiling.
- A Contract-Terms Restriction that barred any contract language between MA plans (or Part D sponsors) and agents, brokers, or TPMOs that could reasonably be expected to inhibit an objective assessment of the best plan for a beneficiary.
- A Consent Requirement that prohibited TPMOs from sharing a beneficiary’s personal information (names, addresses, phone numbers) with other marketing organizations without the beneficiary’s express consent.
These changes aimed to reduce steering incentives. Plaintiffs, including Americans for Beneficiary Choice and the Council for Medicare Choice, filed suit in the Northern District of Texas, arguing the first two provisions exceeded CMS statutory power and violated the Administrative Procedure Act. Judge Reed O’Connor stayed the Fixed Fee and Contract-Terms Restriction in July 2024, allowing only the Consent Requirement to take effect while the case proceeded on the merits.
The Court’s August 18, 2025 Ruling: What Was Vacated
Judge O’Connor granted the plaintiffs’ motions for summary judgment in part. The court vacated the Fixed Fee and the Contract-Terms Restriction, specifically the amendments to 42 C.F.R. §§ 422.2274(a), (c), (d), (e) and the parallel Part D provisions.
Fixed Fee and Reclassification of Administrative Payments
CMS had sought to fold administrative reimbursements (technology, training, marketing support, data security) into the definition of “compensation” and limit them to a flat $100. The court rejected this approach on two independent grounds.
First, the governing statute, 42 U.S.C. § 1395w-21(j)(2)(D), directs the Secretary to establish “guidelines” ensuring that the “use of compensation” creates incentives for agents and brokers to enroll individuals in the plan that best meets their health-care needs. The court read this language narrowly. Congress authorized regulation of how compensation is used, not the power to set rates or engage in ratemaking. Other Medicare statutes explicitly grant rate-setting authority when Congress intends it; this provision does not.
Second, administrative payments are reimbursements for overhead and hard costs, not remuneration for enrollment services. CMS’s own prior regulations had treated them as outside the compensation definition. Reclassifying them now, the court held, stretched the statutory term beyond its ordinary meaning.
The Fixed Fee was also found arbitrary and capricious under the APA. CMS offered insufficient evidence for the specific $100 figure, failed to quantify actual administrative costs despite industry comments, and inadequately addressed reliance interests of existing business models.
Contract-Terms Restriction
The ban on contract provisions that might create incentives inhibiting objective recommendations suffered the same fate. The court concluded it both improperly regulated administrative payments (already outside the compensation definition) and reached terms that have nothing to do with compensation at all, such as renewal conditions or enrollment-volume targets.
A contract renewal clause, for example, governs whether the parties continue doing business; it does not dictate what is paid for a given enrollment. Extending the statute to cover “virtually any contract provision” that could affect objectivity exceeded the limited authority Congress granted.
What Stayed: The Consent Requirement on Beneficiary Data
One provision survived. The court upheld the rule requiring TPMOs to obtain express beneficiary consent before sharing personal data with other marketing organizations.
Judge O’Connor found this measure squarely within CMS’s authority to protect beneficiaries from harmful data practices. The agency had adequately addressed potential HIPAA conflicts and grounded the requirement in documented concerns about unauthorized lead-sharing and aggressive outreach. The Consent Requirement therefore remains in force and continues to apply to plan-year 2025 and beyond.
This distinction matters. While compensation structures regain flexibility, data-sharing practices face a clear, enforceable consent floor. Compliance programs should treat consent documentation as a non-negotiable operational control.
The Post-Chevron Context: Why Loper Bright Mattered
The timing of the decision is significant. In June 2024 the Supreme Court decided Loper Bright Enterprises v. Raimondo, overturning the long-standing Chevron deference doctrine. Under Chevron, courts deferred to an agency’s reasonable interpretation of an ambiguous statute. Loper Bright requires courts to exercise independent judgment about the best reading of the law.
Judge O’Connor expressly applied this standard. He declined to defer to CMS’s expansive reading of “use of compensation” or its functional redefinition of administrative payments. Instead, the court examined the ordinary meaning of the statutory text, compared it with other Medicare provisions that do grant rate-setting power, and concluded CMS had overstepped.
The ruling illustrates the practical impact of Loper Bright on healthcare regulation: agencies can no longer rely on statutory ambiguity to justify novel restrictions. Future CMS proposals on broker compensation will face the same independent judicial scrutiny.
Practical Implications for Industry Stakeholders
For Medicare Advantage Plans and Part D Sponsors
Plans regain the ability to structure administrative payments and contract terms more freely, subject to the pre-2025 framework and the still-effective FMV compensation caps for direct agent and broker commissions. Volume-based incentives and certain renewal conditions that the 2024 rule sought to eliminate are once again permissible, provided they do not otherwise violate existing marketing or anti-kickback rules.
Compliance teams should:
- Review and, if desired, revise TPMO and FMO contracts to restore previously restricted terms.
- Document the rationale for any administrative payment amounts to demonstrate they are genuine reimbursements rather than disguised compensation.
- Ensure systems capture and retain beneficiary consent for any data sharing.
For Agents, Brokers, and TPMOs
The decision restores operational certainty. Field marketing organizations can continue offering technology platforms, training, and lead support without the artificial $100 ceiling. Independent agents regain greater flexibility in how support payments are structured.
At the same time, the Consent Requirement imposes a concrete duty. Sharing names, addresses, or phone numbers without documented consent exposes organizations to enforcement risk. TPMOs should audit data flows, update privacy notices, and train staff on consent capture.
For Compliance Officers and Legal Counsel
The ruling narrows CMS’s regulatory toolkit but does not eliminate oversight. Existing FMV limits on direct compensation, marketing material review requirements, and state licensing rules remain fully in force. Organizations should monitor whether the government appeals to the Fifth Circuit (the deadline for notice of appeal was mid-October 2025) and track any subsequent CMS guidance or new proposed rules for Contract Year 2027.
A practical next step is to map current compensation arrangements against the pre-2025 regulatory baseline and the surviving Consent Requirement. Gap analyses completed now will position organizations to respond quickly if CMS attempts narrower, better-supported restrictions in future rulemaking.
Looking Ahead: Possible Paths for Further Regulation
The vacated provisions cannot simply be reissued in identical form. Any new attempt to limit administrative payments or contract terms will need clearer statutory grounding or more robust evidentiary support to survive Loper Bright review. Congressional legislation expanding CMS authority remains an option, though the current political environment makes rapid action uncertain.
Alternative approaches within existing authority, stronger state-level oversight of marketing practices, or increased funding for independent counseling resources such as State Health Insurance Assistance Programs could also address ongoing concerns about beneficiary steering. Stakeholders should stay engaged in the comment process for upcoming proposed rules.
Key Takeaways from the Medicare Advantage Marketing Rule Judge Decision
The Texas district court vacated the Fixed Fee and Contract-Terms Restriction because they exceeded CMS’s limited statutory power to set guidelines on the use of compensation and because they were arbitrary and capricious under the APA. The Consent Requirement on beneficiary data sharing was upheld and remains enforceable. The decision rests heavily on the post-Chevron independent-judgment standard established by Loper Bright.
Industry participants now operate under a clearer, more flexible compensation framework while retaining a firm obligation to obtain consent before sharing personal beneficiary information. Ongoing vigilance, careful contract review, and readiness for future rulemaking will determine how effectively organizations navigate the next Annual Election Period and beyond.
Frequently Asked Questions
What exactly did the Texas judge vacate in the CMS Medicare Advantage marketing rule?
The court vacated the Fixed Fee provision (the $100 cap on administrative payments and their reclassification as compensation) and the Contract-Terms Restriction that prohibited certain incentive-creating language in contracts with agents, brokers, and TPMOs. The Consent Requirement for sharing beneficiary personal data remains in effect.
Does the decision restore the ability to pay volume-based bonuses?
Yes. Practices the 2024 rule sought to restrict, including certain volume-based incentives and enrollment-tied renewal terms, are again permissible under the pre-2025 framework, subject to remaining FMV compensation limits and other applicable laws.
How does Loper Bright v. Raimondo affect this ruling?
Loper Bright eliminated Chevron deference. Courts must now independently interpret statutes rather than defer to agency readings. Judge O’Connor applied that standard and found CMS’s expansive interpretation of its authority unsupported by the statutory text.
Is the Consent Requirement still enforceable?
Yes. TPMOs may not distribute a beneficiary’s name, address, or phone number to other marketing organizations without the beneficiary’s express consent. This provision was upheld as within CMS authority and continues to apply.
Can CMS issue a new rule with similar compensation caps?
CMS can propose new rules, but any attempt to reimpose rate-setting or broad contract restrictions will face the same statutory and APA scrutiny under Loper Bright. A materially identical rule is unlikely to survive judicial review without stronger statutory grounding.
What should brokers and TPMOs do now?
Review existing contracts for opportunities to restore previously restricted terms, ensure robust consent-capture processes for any data sharing, and monitor CMS guidance and potential appeals. Document the business purpose of administrative payments carefully.
Will this decision affect the upcoming Annual Election Period?
The vacated provisions were already stayed; the ruling simply makes that status permanent. Organizations can operate under the restored flexibility while continuing to comply with the Consent Requirement and all other standing marketing rules.
You May Also Like: Judge Bronwyn Miller: Career, Cases, and Legal Career